PL3154970T3 - Pirolo[2,3-c]pirydyny jako środki do obrazowania splątków neurofibrylarnych - Google Patents
Pirolo[2,3-c]pirydyny jako środki do obrazowania splątków neurofibrylarnychInfo
- Publication number
- PL3154970T3 PL3154970T3 PL15806980T PL15806980T PL3154970T3 PL 3154970 T3 PL3154970 T3 PL 3154970T3 PL 15806980 T PL15806980 T PL 15806980T PL 15806980 T PL15806980 T PL 15806980T PL 3154970 T3 PL3154970 T3 PL 3154970T3
- Authority
- PL
- Poland
- Prior art keywords
- pyridines
- pyrrolo
- imaging agents
- neurofibrilary tangles
- neurofibrilary
- Prior art date
Links
- XLKDJOPOOHHZAN-UHFFFAOYSA-N 1h-pyrrolo[2,3-c]pyridine Chemical class C1=NC=C2NC=CC2=C1 XLKDJOPOOHHZAN-UHFFFAOYSA-N 0.000 title 1
- 239000012216 imaging agent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/079834 WO2015188368A1 (en) | 2014-06-13 | 2014-06-13 | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
| EP15806980.7A EP3154970B1 (en) | 2014-06-13 | 2015-06-09 | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
| PCT/US2015/034794 WO2015191506A2 (en) | 2014-06-13 | 2015-06-09 | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3154970T3 true PL3154970T3 (pl) | 2020-04-30 |
Family
ID=54832744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15806980T PL3154970T3 (pl) | 2014-06-13 | 2015-06-09 | Pirolo[2,3-c]pirydyny jako środki do obrazowania splątków neurofibrylarnych |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9808542B2 (enExample) |
| EP (1) | EP3154970B1 (enExample) |
| JP (1) | JP6513107B2 (enExample) |
| KR (1) | KR102478430B1 (enExample) |
| CN (1) | CN106661018B (enExample) |
| AU (1) | AU2015274843B2 (enExample) |
| BR (1) | BR112016028345B1 (enExample) |
| CA (1) | CA2948528C (enExample) |
| DK (1) | DK3154970T3 (enExample) |
| ES (1) | ES2763095T3 (enExample) |
| HU (1) | HUE048395T2 (enExample) |
| MX (1) | MX375282B (enExample) |
| PL (1) | PL3154970T3 (enExample) |
| RU (1) | RU2695373C2 (enExample) |
| WO (2) | WO2015188368A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012397435B2 (en) | 2012-12-21 | 2017-03-30 | National Institutes For Quantum And Radiological Science And Technology | Novel compound for imaging TAU protein accumulated in the brain |
| WO2018015546A1 (en) | 2016-07-22 | 2018-01-25 | Ac Immune S.A. | Compounds for imaging tau protein aggregates |
| MY196981A (en) | 2016-07-22 | 2023-05-16 | Ac Immune Sa | Compounds for imaging tau protein aggregates |
| JP7256118B2 (ja) | 2017-06-02 | 2023-04-11 | 富士フイルム富山化学株式会社 | アミロイドβ蛋白質量減少剤 |
| JP7282028B2 (ja) | 2017-06-02 | 2023-05-26 | 富士フイルム富山化学株式会社 | 脳萎縮予防または治療剤 |
| US11541033B2 (en) | 2017-06-02 | 2023-01-03 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating Alzheimer's disease |
| MX393700B (es) | 2017-06-02 | 2025-03-24 | Fujifilm Toyama Chemical Co Ltd | Agente para prevenir o tratar la ataxia espinocerebelosa. |
| NZ759657A (en) * | 2017-06-02 | 2022-07-29 | Fujifilm Toyama Chemical Co Ltd | Agent for preventing or treating tauopathy |
| JP7227914B2 (ja) | 2017-10-30 | 2023-02-22 | 富士フイルム富山化学株式会社 | エモパミル結合タンパク質結合剤およびその利用 |
| WO2019145291A1 (en) | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Gamma-carboline compounds for the detection of tau aggregates |
| WO2019145292A1 (en) | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Azacarboline compounds for the detection of tau aggregates |
| CN110343101B (zh) * | 2018-04-04 | 2022-07-12 | 青岛福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
| KR102017324B1 (ko) * | 2018-04-30 | 2019-09-02 | 경북대학교 산학협력단 | 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도 |
| EP3790883A4 (en) | 2018-05-09 | 2022-08-24 | Aprinoia Therapeutics Limited | Heteroaryl compounds and uses thereof |
| US12448374B2 (en) | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| CN108676007B (zh) * | 2018-06-22 | 2020-06-26 | 厦门大学 | 放射性核素标记的苯并蝶啶类衍生物及其制备方法和应用 |
| EP3897670A4 (en) | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| WO2021097243A1 (en) | 2019-11-13 | 2021-05-20 | Aprinoia Therapeutics Inc. | Compounds for degrading tau protein aggregates and uses thereof |
| US20220008563A1 (en) * | 2020-07-10 | 2022-01-13 | The Regents Of The University Of California | Radiolabelled and nonradiolabelled pegylated compounds and uses thereof |
| CA3190418A1 (en) * | 2020-08-06 | 2022-02-10 | Chdi Foundation, Inc. | Heterobiaryl compounds and imaging agents for imaging huntingtin protein |
| CN112939753B (zh) * | 2020-09-15 | 2022-04-05 | 浙江大学 | 一种1-茚酮类化合物的合成方法 |
| KR102240400B1 (ko) | 2020-11-19 | 2021-04-15 | 한국원자력연구원 | 베타-아밀로이드 검출용 수용성 화합물 |
| CN112745299B (zh) * | 2021-01-07 | 2022-01-25 | 温州大学 | 4-氰基-7,8-二氢异喹啉衍生物及其制备方法和应用 |
| TWI782769B (zh) * | 2021-10-28 | 2022-11-01 | 行政院原子能委員會核能研究所 | 一種新穎神經纖維糾結微管相關蛋白質Tau造影化合物、其製備方法及用途 |
| CN114149425A (zh) * | 2021-11-16 | 2022-03-08 | 上海应用技术大学 | 5-氟甲基吡啶衍生物和18-f同位素标记的5-氟甲基吡啶衍生物及其制备与应用 |
| CN114276259B (zh) * | 2022-01-04 | 2022-12-06 | 济川(上海)医学科技有限公司 | 一种马来酸二甲茚定关键中间体的制备方法 |
| CN115417816B (zh) * | 2022-09-05 | 2024-01-26 | 江苏南大光电材料股份有限公司 | 一种3,6-二溴-1-氯-异喹啉的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451566A (en) * | 1993-11-17 | 1995-09-19 | Zeneca Limited | Herbicidal pyrrolopyridine compounds |
| AU2005336513B2 (en) * | 2004-10-07 | 2012-08-09 | Merck Sharp & Dohme Llc | Thiazolyl mGluR5 antagonists and methods for their use |
| US20080027044A1 (en) * | 2006-06-13 | 2008-01-31 | Kim Lewis | Prodrug antibiotic screens |
| WO2008103615A1 (en) | 2007-02-21 | 2008-08-28 | Kalypsys, Inc. | Isoquinolines useful as inducible nitric oxide synthase inhibitors |
| TW200902499A (en) * | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| JP2011521959A (ja) * | 2008-05-30 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | 新規な置換されたインドール |
| CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
| CA2825599C (en) | 2011-02-01 | 2021-07-13 | The Board Of Trustees Of The University Of Illinois | 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors |
| US8684313B2 (en) | 2011-02-02 | 2014-04-01 | Ocean Rodeo Sports Inc. | Inflatable kite with leading edge swept forwards at wingtip |
| US20140348748A1 (en) * | 2011-09-16 | 2014-11-27 | Lisheng Cai | Beta-amyloid imaging agents, methods of manufacture, and methods of use thereof |
| WO2013181075A1 (en) * | 2012-05-29 | 2013-12-05 | Merck Sharp & Dohme Corp. | Isotopically labeled biaryl urea compounds |
| CN103450152B (zh) * | 2012-06-04 | 2015-11-18 | 济南海乐医药技术开发有限公司 | 基于吲唑、吲哚或氮杂吲唑、氮杂吲哚的双芳基脲类结构抗肿瘤药物 |
| GB201304526D0 (en) * | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| GB201404498D0 (en) * | 2014-03-13 | 2014-04-30 | Proximagen Ltd | New compounds |
-
2014
- 2014-06-13 WO PCT/CN2014/079834 patent/WO2015188368A1/en not_active Ceased
-
2015
- 2015-06-09 AU AU2015274843A patent/AU2015274843B2/en active Active
- 2015-06-09 HU HUE15806980A patent/HUE048395T2/hu unknown
- 2015-06-09 JP JP2016572520A patent/JP6513107B2/ja active Active
- 2015-06-09 RU RU2016150404A patent/RU2695373C2/ru active
- 2015-06-09 ES ES15806980T patent/ES2763095T3/es active Active
- 2015-06-09 DK DK15806980.7T patent/DK3154970T3/da active
- 2015-06-09 PL PL15806980T patent/PL3154970T3/pl unknown
- 2015-06-09 BR BR112016028345-7A patent/BR112016028345B1/pt active IP Right Grant
- 2015-06-09 EP EP15806980.7A patent/EP3154970B1/en active Active
- 2015-06-09 CA CA2948528A patent/CA2948528C/en active Active
- 2015-06-09 US US15/317,333 patent/US9808542B2/en active Active
- 2015-06-09 WO PCT/US2015/034794 patent/WO2015191506A2/en not_active Ceased
- 2015-06-09 KR KR1020177000709A patent/KR102478430B1/ko active Active
- 2015-06-09 CN CN201580031335.2A patent/CN106661018B/zh active Active
- 2015-06-09 MX MX2016016384A patent/MX375282B/es active IP Right Grant
-
2017
- 2017-10-04 US US15/724,402 patent/US10022461B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX375282B (es) | 2025-03-06 |
| JP6513107B2 (ja) | 2019-05-15 |
| US9808542B2 (en) | 2017-11-07 |
| DK3154970T3 (da) | 2020-01-20 |
| US20180071412A1 (en) | 2018-03-15 |
| CN106661018B (zh) | 2019-07-19 |
| BR112016028345A2 (pt) | 2017-08-22 |
| KR20170016481A (ko) | 2017-02-13 |
| RU2019115483A (ru) | 2019-06-13 |
| KR102478430B1 (ko) | 2022-12-15 |
| US20170119912A1 (en) | 2017-05-04 |
| BR112016028345A8 (pt) | 2021-06-29 |
| EP3154970A4 (en) | 2017-11-15 |
| MX2016016384A (es) | 2017-05-01 |
| CA2948528C (en) | 2022-05-31 |
| EP3154970B1 (en) | 2019-11-06 |
| WO2015188368A1 (en) | 2015-12-17 |
| JP2017521387A (ja) | 2017-08-03 |
| ES2763095T3 (es) | 2020-05-27 |
| CN106661018A (zh) | 2017-05-10 |
| RU2016150404A (ru) | 2018-07-18 |
| CA2948528A1 (en) | 2015-12-17 |
| US10022461B2 (en) | 2018-07-17 |
| HUE048395T2 (hu) | 2020-08-28 |
| AU2015274843B2 (en) | 2018-11-22 |
| RU2016150404A3 (enExample) | 2018-11-30 |
| EP3154970A2 (en) | 2017-04-19 |
| WO2015191506A2 (en) | 2015-12-17 |
| BR112016028345B1 (pt) | 2022-11-29 |
| AU2015274843A1 (en) | 2016-11-10 |
| WO2015191506A3 (en) | 2016-02-04 |
| RU2695373C2 (ru) | 2019-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3154970T3 (pl) | Pirolo[2,3-c]pirydyny jako środki do obrazowania splątków neurofibrylarnych | |
| IL275365A (en) | 6-Azaindole compounds | |
| IL261158B (en) | Tetracyclic pyridone compounds as antivirals | |
| IL252053A0 (en) | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders | |
| IL247527A0 (en) | Herbicidal preparations containing isoxazolo[4,5–b]pyridines | |
| ZA201808257B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| IL251164A0 (en) | Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao | |
| IL247599B (en) | Formulation that suppresses the immune system | |
| IL250682A0 (en) | A method for the preparation of 2'-o-fucosyl lactose | |
| GB2531940B (en) | Process for preparing methotrexate formulation | |
| PL2949650T3 (pl) | Syntetyczny sposób otrzymywania 1,2-benzoizotiazolin-3-onu | |
| IL259557A (en) | Methods for the preparation of modified 6,5-dihydro-6-phenyl-benzo[f]isoquinoline-2-amine | |
| IL251166A0 (en) | Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao | |
| HUE038764T2 (hu) | 2,7-Diazaspiro[3.5]nonán vegyületek | |
| ZA201701093B (en) | Aryl-triazolyl pyridines as pest control agents | |
| DK3330264T3 (en) | Pyridin substitueret 2-aminopyridin proteinkinase-inhibitorkrystal | |
| GB201522532D0 (en) | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives | |
| SG10201600362SA (en) | Methods For Optimising Parameters | |
| AU5623P (en) | PS-3.108 Fragaria Xananassa | |
| GB201421404D0 (en) | Seat 19 | |
| GB201408218D0 (en) | Seat 15 |